Noveome Biotherapeutics
Noveome Biotherapeutics: Clinical-stage company pioneering regenerative therapies for damaged tissues.
Founded
2000Noveome Biotherapeutics: Clinical-stage company pioneering regenerative therapies for damaged tissues.
Noveome Biotherapeutics, founded to pioneer regenerative therapies, is a clinical-stage company dedicated to the repair of inflamed or damaged tissues. Their core mission is to develop breakthrough treatments that harness biologic components to promote anti-inflammatory, neuroprotective, anti-apoptotic, and vascular integrity preservative properties. Their flagship product, ST266, is a multi-targeted secretome containing hundreds of biologically active proteins and factors essential for neuroprotection, inflammation modulation, cell recovery, and healing. Noveome primarily focuses on addressing conditions such as necrotizing enterocolitis in neonates.
Notable achievements of Noveome Biotherapeutics include receiving rare pediatric disease designation and orphan drug designation for their treatment of necrotizing enterocolitis. The company has garnered attention from key investors and industry experts due to its innovative approach and potential to simulate natural healing processes. Through its advanced biologic therapies, Noveome aims to make a significant impact on regenerative medicine and improve outcomes for patients with severe tissue damage and inflammation.
Companies similar to Noveome Biotherapeutics include Secretome Therapeutics, Novoron Bioscience, Novome Biotechnologies and Nuo Therapeutics.
Noveome Biotherapeutics was founded in 2000.
Noveome Biotherapeutics' headquarters is located in Pittsburgh, PA, US.
Noveome Biotherapeutics' most recent funding round was for $20.7M (USD) in August 2023.
As of Aug 17, 2023, Noveome Biotherapeutics has raised a total of $43.3M (USD).
Noveome Biotherapeutics has 24 employees as of Feb 5, 2024.
Novome Biotechnologies
